UniQure Faces Setback as FDA Prefers Randomized Trial for Huntington’s Treatment
UniQure’s stock experienced a decline on Monday following unfavorable feedback from the FDA regarding its Huntington’s disease program, AMT-130. The agency indicated that the current application lacks sufficient data to support its approval, specifically expressing a preference for a randomized clinical trial to validate the treatment’s efficacy. This development underscores the FDA’s stringent requirements for…









